Aquestive Therapeutics, Inc. Interest Expense Nonoperating
Aquestive Therapeutics, Inc. (AQST) reported Interest Expense Nonoperating of $2.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Aquestive Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $2.81M, a 0.93% increase year-over-year.
- Aquestive Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $2.90M, a 4.35% increase year-over-year.
- Aquestive Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $2.78M, a 0.04% decline year-over-year.
- Aquestive Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $2.78M, a 0.04% decline year-over-year.
- Aquestive Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $11.12M, a 0.02% decline from fiscal 2024.
- Aquestive Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $11.12M, a 75.51% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $6.34M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.81M 10-Q · filed 2026-08-11 | $5.71M 10-Q · filed 2026-08-11 | $8.49M derived: sum of 3 quarters · filed 2026-08-11 | $11.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.90M 10-Q · filed 2026-05-13 | $5.68M derived: sum of 2 quarters · filed 2026-05-13 | $8.46M derived: sum of 3 quarters · filed 2026-05-13 | $11.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.56M derived: sum of 2 quarters · filed 2026-03-04 | $8.34M derived: sum of 3 quarters · filed 2026-08-11 | $11.12M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.78M 10-Q · filed 2025-11-05 | $5.56M derived: sum of 2 quarters · filed 2026-08-11 | $8.34M 10-Q · filed 2025-11-05 | $11.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.78M 10-Q · filed 2026-08-11 | $5.56M 10-Q · filed 2026-08-11 | $8.34M derived: sum of 3 quarters · filed 2026-08-11 | $11.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.78M 10-Q · filed 2026-05-13 | $5.56M derived: sum of 2 quarters · filed 2026-05-13 | $8.34M derived: sum of 3 quarters · filed 2026-05-13 | $11.12M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.56M derived: sum of 2 quarters · filed 2026-03-04 | $8.34M derived: sum of 3 quarters · filed 2026-03-04 | $11.12M 10-K · filed 2026-03-04 |
| 2024-09-30 | $2.78M 10-Q · filed 2025-11-05 | $5.56M derived: sum of 2 quarters · filed 2025-11-05 | $8.34M 10-Q · filed 2025-11-05 | $10.62M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.78M 10-Q · filed 2025-08-11 | $5.56M 10-Q · filed 2025-08-11 | $7.84M derived: sum of 3 quarters · filed 2025-08-11 | $9.09M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.78M 10-Q · filed 2025-05-12 | $5.06M derived: sum of 2 quarters · filed 2025-05-12 | $6.31M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $3.53M derived: sum of 2 quarters · filed 2025-03-05 | $6.34M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $1.26M 10-Q · filed 2024-11-04 | $4.06M 10-Q · filed 2024-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |